|
ZNF594 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.27438076652697E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73969727512713E-11 |
| Normal-vs-Stage2 |
4.06909994588034E-09 |
| Normal-vs-Stage3 |
1.86761717202444E-12 |
| Normal-vs-Stage4 |
1.71107572555229E-12 |
| Stage1-vs-Stage2 |
3.636800E-01 |
| Stage1-vs-Stage3 |
3.437900E-02 |
| Stage1-vs-Stage4 |
7.838100E-03 |
| Stage2-vs-Stage3 |
2.057900E-02 |
| Stage2-vs-Stage4 |
5.656900E-03 |
| Stage3-vs-Stage4 |
3.044400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.99125177352744E-12 |
| Normal-vs-AfricanAmerican |
1.31240000000865E-06 |
| Normal-vs-Asian |
1.00270014513626E-10 |
| Caucasian-vs-AfricanAmerican |
6.504200E-01 |
| Caucasian-vs-Asian |
5.994400E-01 |
| AfricanAmerican-vs-Asian |
9.518400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.35389477406989E-11 |
| Normal-vs-Female |
2.66409116989053E-12 |
| Male-vs-Female |
6.501600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.65201227434409E-12 |
| Normal-vs-Age(41-60Yrs) |
7.41473549226157E-12 |
| Normal-vs-Age(61-80Yrs) |
6.92634838372896E-12 |
| Normal-vs-Age(81-100Yrs) |
1.781750E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.443000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.889800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.866800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.540800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.219800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.118400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.48089999987933E-07 |
| Classical-VS-Follicular |
2.413200E-01 |
| Classical-VS-Other |
5.902200E-01 |
| Classical-VS-Normal |
2.85099721608617E-11 |
| Tall-VS-Follicular |
6.41039999971227E-07 |
| Tall-VS-Other |
1.130780E-01 |
| Tall-VS-Normal |
5.55111512312578E-16 |
| Follicular-VS-Other |
7.204800E-01 |
| Follicular-VS-Normal |
1.46140000101269E-09 |
| Other-VS-Normal |
1.550120E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.21089837945965E-11 |
| Normal-vs-N1 |
2.80464540480807E-12 |
| N0-vs-N1 |
1.087810E-01 |
|
|
